Novo Nordisk enters research partnerships with biotech firms
01/04/2024 22:19
Novo Nordisk (NVO) announced a new R&D deal with two US biotech firms valued at $1.1 billion, in an attempt to keep up with competition on obesity drugs and expand treatments for a liver disease known as MASH (Metabolic Dysfunction-associated Steatohepatitis). The biotech firms listed were Omega Therapeutics (OMGA) and Cellarity, which are under the umbrella of Flagship Pioneering. Yahoo Finance Anchors Madison Mills and Seana Smith break down the latest developments with these companies and what it could mean moving forward. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Nicholas Jacobino.
Novo Nordisk (NVO) announced a new R&D deal with two US biotech firms valued at $1.1 billion, in an attempt to keep up with competition on obesity drugs and expand treatments for a liver disease known as MASH (Metabolic Dysfunction-associated Steatohepatitis).
The biotech firms listed were Omega Therapeutics (OMGA) and Cellarity, which are under the umbrella of Flagship Pioneering.
Yahoo Finance Anchors Madison Mills and Seana Smith break down the latest developments with these companies and what it could mean moving forward.
For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Editor's note: This article was written by Nicholas Jacobino.